Cenk Ayata1. 1. Neurovascular Research Lab, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, MA 02129, USA. cayata@partners.org
Abstract
BACKGROUND: Spreading depression (SD) is the electrophysiological substrate of migraine aura and a potential trigger for headache. Since its discovery by Leão in 1944, SD has transformed from being viewed as an epiphenomenon into a therapeutic target relevant in the pathophysiology of migraine and brain injury. AIM: Despite decades of research, the underpinnings of SD are still poorly understood, hampering our efforts to selectively block its initiation and spread. Experimental models have nevertheless been useful to measure the likelihood of SD occurrence (i.e. SD susceptibility) and characterize genetic, physiological and pharmacological modulation of SD in search of potential therapies, such as in migraine prophylaxis and stroke. Here, I review experimental SD susceptibility endpoints and surrogates, and minimum essential model requirements to improve their utility in drug screening. CONCLUSION: A critical reappraisal of strengths and caveats of experimental models of SD susceptibility is needed to set standards and improve data quality, interpretation and reconciliation.
BACKGROUND: Spreading depression (SD) is the electrophysiological substrate of migraine aura and a potential trigger for headache. Since its discovery by Leão in 1944, SD has transformed from being viewed as an epiphenomenon into a therapeutic target relevant in the pathophysiology of migraine and brain injury. AIM: Despite decades of research, the underpinnings of SD are still poorly understood, hampering our efforts to selectively block its initiation and spread. Experimental models have nevertheless been useful to measure the likelihood of SD occurrence (i.e. SD susceptibility) and characterize genetic, physiological and pharmacological modulation of SD in search of potential therapies, such as in migraine prophylaxis and stroke. Here, I review experimental SD susceptibility endpoints and surrogates, and minimum essential model requirements to improve their utility in drug screening. CONCLUSION: A critical reappraisal of strengths and caveats of experimental models of SD susceptibility is needed to set standards and improve data quality, interpretation and reconciliation.
Authors: David Y Chung; Kazutaka Sugimoto; Paul Fischer; Maximilian Böhm; Tsubasa Takizawa; Homa Sadeghian; Andreia Morais; Andrea Harriott; Fumiaki Oka; Tao Qin; Nils Henninger; Mohammad A Yaseen; Sava Sakadžić; Cenk Ayata Journal: J Neurosci Methods Date: 2018-09-05 Impact factor: 2.390
Authors: Mustafa Balkaya; Jessica L Seidel; Homa Sadeghian; Tao Qin; David Y Chung; Katharina Eikermann-Haerter; Arn M J M van den Maagdenberg; Michel D Ferrari; Cenk Ayata Journal: Neuroscience Date: 2019-07-09 Impact factor: 3.590
Authors: David Y Chung; Homa Sadeghian; Tao Qin; Sevda Lule; Hang Lee; Fahri Karakaya; Stacy Goins; Fumiaki Oka; Mohammad A Yaseen; Thijs Houben; Else A Tolner; Arn M J M van den Maagdenberg; Michael J Whalen; Sava Sakadžic; Cenk Ayata Journal: Cereb Cortex Date: 2019-03-01 Impact factor: 5.357
Authors: Thijs Houben; Inge Cm Loonen; Serapio M Baca; Maarten Schenke; Johanna H Meijer; Michel D Ferrari; Gisela M Terwindt; Rob A Voskuyl; Andrew Charles; Arn Mjm van den Maagdenberg; Else A Tolner Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: Edgar Santos; Fiorella León; Humberto Silos; Renan Sanchez-Porras; C William Shuttleworth; Andreas Unterberg; Oliver W Sakowitz Journal: J Cereb Blood Flow Metab Date: 2016-09-28 Impact factor: 6.200